Search

Displaying results 7901 - 7910 of 10000 in total
  1. Drug

    Rogaratinib

    go.drugbank.com/drugs/DB15078
    Investigational

    Rogaratinib is under investigation in clinical trial NCT03762122 (Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)).

  2. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other … This recombinant BCG, VPM1002, has been created in response and investigated for preventing pulmonary TB in newborns and TB recurrence in adults through post-exposure immunization.

  3. Drug

    Opaganib

    go.drugbank.com/drugs/DB12764
    Investigational

    Opaganib, also known as ABC294640, is a selective [sphingosine kinase-2 (SK2)](https://go.drugbank.com/polypeptides/Q9NRA0) inhibitor that is orally administered. … [L27436] This drug has potential anticancer, anti-inflammatory, and antiviral activities, with potential applications in oncology, inflammation, the gastrointestinal system, and COVID-19.

  4. Drug

    Emactuzumab

    go.drugbank.com/drugs/DB14905
    Investigational

    Emactuzumab is under investigation in clinical trial NCT01494688 (A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors).

  5. Drug

    Satavaptan

    go.drugbank.com/drugs/DB14923
    Investigational

    Satavaptan is under investigation in clinical trial NCT00359437 (Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver).

  6. Drug

    HQP1351

    go.drugbank.com/drugs/DB16185
    Investigational

    HQP1351 is under investigation in clinical trial NCT03883100 (A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation).

  7. Drug

    Luvixasertib

    go.drugbank.com/drugs/DB19200
    Investigational

    Luvixasertib is under investigation in clinical trial NCT05251714 (CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer).

    Synonyms: Benzamide, n-cyclopropyl-4-(7-(((cis-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(3-pyridinyloxy)pyrazolo(1,5-a)pyrimidin-3-yl)-2-methyl-, N-cyclopropyl-4-(7-(((cis-3-hydroxy-3-methylcyclobutyl)methyl)amino)-5-(3-pyridinyloxy)pyrazolo(1,5-a)pyrimidin-3-yl)-2-methylbenzamide
  8. Drug

    Cotadutide

    go.drugbank.com/drugs/DB15194
    Investigational

    Cotadutide is under investigation in clinical trial NCT03444584 (Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Subject With Type 2 Diabetes).

  9. Drug

    CYNK-001

    go.drugbank.com/drugs/DB15722
    Investigational

    CYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.

  10. Drug

    VB10.16

    go.drugbank.com/drugs/DB17512
    Investigational

    It is composed of three parts, one encodes the E6/E7 fusion protein of human papillomavirus (HPV) type 16 (HPV16), a dimerization entity, and the part encoding a protein that specifically binds to antigen-presenting … VB10.16 is a novel therapeutic antigen-presenting cell-targeting DNA vaccine developed to treat HPV16-positive cancers.